Comparative ARB pharmacology

British Journal of Cardiology

Volumn 17, Issue SUPPL. 2, 2010, Pages

  Meredith, Peter ^a  

^a Gardiner Institute   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; CANDESARTAN; EPROSARTAN; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; OLMESARTAN; TELMISARTAN; THIAZIDE DIURETIC AGENT; VALSARTAN;

BINDING AFFINITY; BINDING SITE; CARDIOVASCULAR RISK; CHEMICAL STRUCTURE; DRUG EFFICACY; DRUG MEGADOSE; GASTROINTESTINAL TRACT; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LICENSING; LOW DRUG DOSE; META ANALYSIS (TOPIC); PERIPHERAL OCCLUSIVE ARTERY DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR BINDING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK; SHORT SURVEY; STROKE;

EID: 78751691089     PISSN: 09696113     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (11)

1. 1 receptor binding and protection by candesartan: comparison to other biphenyl-tetrazole sartans. J Hypertens 2006;24:S23-S30.
2. Bhuiyan MA, Ishiguro M, Hossain M et al. Binding sites of valsartan, candesartan and losartan with angiotensin II receptor 1 subtype by molecular modeling. Life Sciences 2009;85(3-4): 136-40.
3. Belz GG, Fuchs B, Malerczyk C, Magin SG, Roll S, Mutschler E. Inhibition of angiotensin II pressor response and ex vivo angiotensin II radioligand binding by candesartan cilexetil and losartan in healthy human volunteers. J Hum Hypertens 1997;11(Suppl 2):S45-S47.
4. 1 receptor interactions: in vitro evidence for insurmountable antagonism and inverse agonism. Mol Cell Endocrinol 2009;302(2):237-43.
5. Lacourcière Y, Asmar R. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesartan/Losartan study investigators. Am J Hypertens 1999;12(12 Pt 1-2):1181-7.
6. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360(9349):1903-13. (Pubitemid 35472129)
7. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665.doi:10.1136/bmj.b1665
8. 1-receptor blockers. Differences in potency and efficacy. Blood Press 2002;11:293-301.
9. Meredith PA, Murray LS, McInnes GT. Comparison of the efficacy of candesartan and losartan: a meta-analysis of trials in the treatment of hypertension. J Hum Hypertens 2009;1-7. Advance online publication, 17 December 2009;doi:10.1038/jhh.2009.99.
10. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis of 11 000 participants from 42 trials. Am J Med 2009;122:290-300.
11. Kjeldsen SE, Stålhammar J, Hasvold P, Bodegard J, Olsson U, Russell D. Effects of losartan vs. candesartan in reducing cardiovascular events in the primary treatment of hypertension. J Hum Hypertens 2010;24:2634-73. Advance online publication, 5 November 2009;